Suppr超能文献

慢性阻塞性肺疾病(COPD)和肺癌患者中戒烟药物治疗的应用情况。

Utilization of smoking-cessation pharmacotherapy among chronic obstructive pulmonary disease (COPD) and lung cancer patients.

作者信息

Vaidya Varun, Hufstader-Gabriel Meghan, Gangan Nilesh, Shah Surbhi, Bechtol Robert

机构信息

University of Toledo , Toledo, OH , USA.

出版信息

Curr Med Res Opin. 2014 Jun;30(6):1043-50. doi: 10.1185/03007995.2014.884493. Epub 2014 Feb 5.

Abstract

OBJECTIVE

Smoking is one of the major risk factors causing morbidity and mortality in chronic obstructive pulmonary disease (COPD) and lung cancer patients. Use of smoking cessation pharmacotherapy is an effective way to help quit smoking. The purpose of the study was to determine the prevalence of smoking and the proportion of patients using smoking cessation agents, and to identify the socio-demographic factors that affect the use of these agents among COPD and lung cancer patients.

RESEARCH DESIGN AND METHODS

A retrospective study was done to identify smokers having COPD (ICD-9: 490-492) or lung cancer (ICD-9: 162), and those who use smoking cessation agents from 2006-2010, using Medical Expenditure Panel Survey (MEPS) data. A multiple logistic regression model was built to identify significant socio-demographic predictors associated with the use of smoking cessation agents.

RESULTS

Around 16.8% of COPD patients and 15.1% of lung cancer patients reported smoking after diagnosis. Out of the total smokers, 8.8% patients with COPD and 12.6% patients with lung cancer reported use of smoking cessation agents during the 5 year period. Logistic regression showed that odds for smoking cessation use in COPD patients were lower for Hispanics (OR = 0.107, 95% CI 0.023-0.502) and higher for patients having insurance coverage (OR = 3.453, 95% CI 1.240-9.617).

CONCLUSION

Results showed that a large number of patients continued to smoke even after the diagnosis of COPD and lung cancer; whereas only a few among them used smoking cessation agents. Ethnicity disparities and insurance status were associated with the use of smoking cessation agents. Differential use among population sub-groups suggests a requirement for need based smoking cessation programs and appropriate prescription drug coverage. Further research needs to be done to evaluate reasons for disparities in smoking cessation agents' use. The study had limitations common to research designs based on observational and self-reported datasets.

摘要

目的

吸烟是导致慢性阻塞性肺疾病(COPD)和肺癌患者发病和死亡的主要危险因素之一。使用戒烟药物疗法是帮助戒烟的有效方法。本研究的目的是确定吸烟率以及使用戒烟药物的患者比例,并确定影响COPD和肺癌患者使用这些药物的社会人口学因素。

研究设计与方法

采用回顾性研究,利用医疗支出面板调查(MEPS)数据,确定2006年至2010年期间患有COPD(国际疾病分类第九版:490 - 492)或肺癌(国际疾病分类第九版:162)的吸烟者以及使用戒烟药物的吸烟者。建立多元逻辑回归模型,以确定与使用戒烟药物相关的显著社会人口学预测因素。

结果

约16.8%的COPD患者和15.1%的肺癌患者在诊断后报告仍在吸烟。在所有吸烟者中,8.8% 的COPD患者和12.6% 的肺癌患者在5年期间报告使用了戒烟药物。逻辑回归显示,西班牙裔COPD患者使用戒烟药物的几率较低(比值比 = 0.107,95%置信区间0.023 - 0.502),而有保险的患者使用几率较高(比值比 = 3.453,95%置信区间1.240 - 9.617)。

结论

结果表明,大量患者即使在被诊断为COPD和肺癌后仍继续吸烟;而其中只有少数人使用了戒烟药物。种族差异和保险状况与戒烟药物的使用有关。人群亚组之间使用情况存在差异表明需要基于需求的戒烟计划和适当的处方药覆盖范围。需要进一步研究以评估戒烟药物使用差异的原因。本研究具有基于观察性和自我报告数据集的研究设计所共有的局限性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验